# Clinical guideline committee

<table>
<thead>
<tr>
<th>Role</th>
<th>Members</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair</td>
<td>Gisela Terwindt</td>
</tr>
<tr>
<td>Vice Chairs</td>
<td>Chris Diener and Cristina Tassorelli</td>
</tr>
<tr>
<td>Members</td>
<td>Messoud Ashina, Peter Goadsby, Elizabeth Leroux, Richard Lipton, Patricia Pozo-Rosich, Shuu-Jiun Wang</td>
</tr>
<tr>
<td>Juniors</td>
<td>Daniele Martinelli (I), Thomas van den Hoek (NL), Marie Deen (D)</td>
</tr>
</tbody>
</table>
Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults


Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults

Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine in children and adolescents, 1st edition

Previous deliverables
Previous deliverables by junior members

Adherence to the 2008 IHS guidelines for controlled trials of drugs for the preventive treatment of chronic migraine in adults

Marie Deen, Daniele Martinelli, Judith Pijpers, Hans-Christoph Diener, Stephen Silberstein, Michel D Ferrari, Messoud Ashina, Cristina Tassorelli, and Hsiangkuo Yuan

Have the IHS Guidelines for controlled trials of acute treatment of migraine attacks been followed? Laying the ground for the 4th edition

Alicia Alpuente, Cristina Tassorelli, Hans-Christoph Diener, Stephen D Silberstein, and Patricia Pozo-Rosich
Guidelines of the International Headache Society for clinical trials with neuromodulation devices for the treatment of migraine

Cristina Tassorelli1,2, Hans Christoph Diener3,4,6, Stephen D Silberstein4,6, David W Dodick5, Peter J Goadsby6,7, Rigmor H Jensen8, Delphine Magis9, Patricia Pozo-Rosich10, Hsiangkuo Yuan6, Daniele Martinelli1,2, Thomas van den Hoek11, Marie Deen6, Messoud Ashina8, and Gisela M Terwindt11

Health technology assessment for the acute and preventive treatment of migraine: A position statement of the International Headache Society

Hans Christoph Diener1,6, Messoud Ashina2, Isabelle Durand-Zaleski3,4, Tobias Kurth5, Michel Lantéri-Minet6, Richard B Lipton7, Daniel A Ollendorf8, Patricia Pozo-Rosich9,10, Cristina Tassorelli1,11, and Gisela M Terwindt11
Guidelines of the International Headache Society for Controlled Trials in Cluster Headache

**Expected 2022**

IHS Clinical Trials Committee – Guidelines review process

- Draft 1 final author approved – to Clinical Trials Committee members non-authors for review
- Revision
- Draft 2 – to IHS Board, IHS Advisory Council for review
- Revision
- Draft 3 – to Corporate Roundtable members, IHS members for review
- Revision
- Draft 4 – to regulatory bodies for review
- Revision
- Draft 4 – to IHS Board for approval, medical writer for review and submission preparation
- Revision
- Submission to Cephalalgia

All review and revision periods – 2 weeks
Guidelines of the International Headache Society for Controlled Trials for Idiopathic Intracranial Hypertension

Guidelines of the International Headache Society for Controlled Trials for Persistent Post-Traumatic Headache (PPTH) attributed to Mild Traumatic Brain Injury.